MRNA · Healthcare

Moderna, Inc.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-07

Revenue Performance and MixImportance 74 · Surprise 32
Moderna reported second-quarter 2026 revenue of $145 million, exceeding analysts’ estimates. The company posted a GAAP loss of $1.97 per share for the quarter. Management reiterated a 2026 revenue-growth target of up…
Guidance / OutlookImportance 59 · Surprise 32
On its second-quarter 2026 earnings call, Moderna reiterated a target of up to 10% revenue growth for full-year 2026. Management also tightened its cost-of-sales and research-and-development guidance while emphasizing…

Litigation Settlement ExposureImportance 71 · Surprise 60
Roivant reported receiving a settlement payment from Moderna related to litigation, with third-party reports citing $771.6 million collected in July 2026 and another report citing a $950 million payment. The settlement…

Regulatory Approval MilestonesImportance 44 · Surprise 60
The U.S. Food and Drug Administration approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based seasonal influenza vaccine. It is authorized for adults aged 50 and older, with traditional approval for ages 50–64…
Operating Expense TrendsImportance 37 · Surprise 42
Moderna’s second-quarter 2026 earnings call emphasized cost reductions alongside pipeline investment. Management tightened its 2026 cost-of-sales and research-and-development guidance, although the digest did not…
Litigation and Legal RiskImportance 37 · Surprise 42
Moderna appealed a district court judgment concerning alleged patent infringement related to its COVID-19 vaccines to the U.S. Court of Appeals for the Federal Circuit. The company argues under 28 U.S.C. §1498(a) that…

Revenue Performance and MixImportance 74 · Surprise 32
Moderna reported second-quarter 2026 revenue of $145 million, exceeding analysts’ estimates. The company posted a GAAP loss of $1.97 per share for the quarter. Management reiterated a 2026 revenue-growth target of up…
Operating Expense TrendsImportance 37 · Surprise 42
Moderna’s second-quarter 2026 earnings call emphasized cost reductions alongside pipeline investment. Management tightened its 2026 cost-of-sales and research-and-development guidance, although the digest did not…
Product / Drug Pipeline ProgressImportance 31 · Surprise 42
Moderna initiated a Phase 1 clinical trial in Canada for mRNA-1469, an investigational vaccine against Bundibugyo ebolavirus disease. The study is expected to enroll approximately 80 healthy adults and will evaluate…